| 13:00 – 14:30 | Panel I: Yeni tanı kriterlerinin ışığında MS’te biyobelirteçler: MR ve diğer biyobelirteçler
Oturum Başkanları: Murat Terzi, M. Ufuk Aluçlu |
||
| Panelistler: Özlem Ethemoğlu, Atay Vural, Bilgin Öztürk, Sedat Şen, Mehmet Fatih Yetkin |
|||
| 14:30 – 15:15 | Uydu Sempozyumu - Abdi İbrahim Chair: Hüsnü Efendi |
||
| Dimetil Fumarat ve Teriflunomid Tedavisinde Güncel Veriler ve MS’te Engellilik Kavramına Bakış Serkan Demir, Mehmet Fatih Yetkin |
|||
| 15:15 - 15:30 | Ara  |
||
| 15:30 – 17:00 | Panel II: MS’te tedavi seçenekleri ve uygulamaları Oturum Başkanları: Ömer Faruk Turan, Egemen İdiman |
||
| Panelistler: Kadriye Ağan, Esra Gürsoy, Alev Leventoğlu, Semra Mungan, Cihat Uzunköprü, Destan Bünül |
|||
| 17:00-17:45 | Uydu Sempozyumu - Sanovel Chairs: Ayşe Altıntaş, Özlem Ethemoğlu |
||
| Speakers: Mesude Tütüncü, Rabia Gökçen Gözübatık Çelik |
|||
| 17:45-18:00 | Ara |
||
| 18:00- 19:00 | Panel III: Genç Araştırmacılar ve Avrupa Charcot Vakfı Burs Topluluğu Özel Oturumu | ||
| 19:00-20:00 | Panel IV: MS’te Rehabilitasyon Oturumu Oturum Başkanları: Aysun Ünal, Gürdal Orhan |
||
| Panelist: Kognitif Rehabilitasyon: Serkan Özakbaş |
|||
| Panelist: Fiziksel Rehabilitasyon: Mesrure Köseoğlu |
|||
| Panelist: Yapay Zeka- Beyin Bilgisayar: Tuncay Gündüz |
|||
| 20:00 – 20: 20 | Akılcı İlaç Oturumu Oturum Başkanı: Tahir Kurtuluş Yoldaş |
||
| Panelist: Abdulkadir Tunç |
|||
| 20:20-21:00 | Ara & Açık Büfe | ||
| 21:00-23:00 | Panel V: TANI GECESİ: MS VE İLİŞKİLİ HASTALIKLAR Oturum Başkanı: Sabahattin Saip |
||
| Panelistler: Taşkın Duman, Özgül Ekmekçi, Sıla Usar, Burcu Altunrende, Haluk Gümüş Vaka Sunumları: Gökçen Gözübatık Çelik, Ali Özhan Sıvacı, İpek Güngör Doğan, Pınar Acar Özen, Bedriye Karaman, Duygu Arslan Mehdiyev |
|||
| 08:00-09:00 | Poster Sessions | ||
| 09:00-09:15 | OFFICIAL OPENING & Presentation of the Istanbul MS days awards Chairs: Rana Karabudak, Husnu Efendi, Orhun H. Kantarci, Aksel Siva |
||
| 09:00-09:15 | Opening address and a quick overview of the 10 years of Istanbul MS days Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi & Jack P. Antel |
||
| 09:15-09:30 | Welcome address 1: The 45 years of MS in 15 minutes Aksel Siva |
||
| 09:30-09:45 | Welcome address 2: Rumi: Between the absolutes of doing it wrong and right Orhun H. Kantarci |
||
| 09:45-10:00 | Presentation of the Istanbul MS days award Aksel Siva, Rana Karabudak, Orhun H. Kantarci, Husnu Efendi |
||
| 10:00-10:30 | Istanbul MS Days: Learning from our mistakes in defining diseases Brain G. Weinshenker |
||
| 10:30-10:45 | Break |
||
| 10:45-12:30 | SESSION-1: Learning from mistakes in science Discussants & Chairs: Frauke Zipp, Riadh Gouider, Cavit Boz |
||
| 10:45-11:00 | Introduction to the session: "Opportunities lost by dismissing or trivializing negative findings in MS research?" Frauke Zipp |
||
| 11:00-11:20 | Learning from Mistakes Janet Hafler |
||
| 11:20-11:40 | Mistakes in the society Boris Zalc |
||
| 11:40-12:00 | Pitfalls of genomic “big-data” Philip L. De Jager |
||
| 12:00-12:30 | Q & A, Discussion | ||
| 12:30-13:30 | Lunch & In-Lunch Satellite Symposium | ||
| 13:30-15:00 | SESSION-2: Microglia in MS Discussants & Chairs:Jack P. Antel, Samia Khoury, Erdem Tüzün |
||
| 13:30-13:45 | Introduction to the session - The old friend or new foe: why did we ignore microglia all these years? Jack P. Antel |
||
| 13:45-14:05 | Dynamic and changing roles of microglia in MS Bruce Trapp |
||
| 14:05-14:25 | More questions than answers from BTK inhibitor research in MS Amit Bar-Or |
||
| 14:25-14:45 | Molecular imaging is the answer - Why are you afraid of PET? Laura Airas |
||
| 14:45-15:15 | Q & A, Discussion | ||
| 15:15-15:30 | Break |
||
| 15:30-17:30 | SESSION-3: Modeling MS in the future Discussants & Chairs:Tanja Kuhlmann, Husnu Efendi, Magd Zakaria |
||
| 15:30-15:45 | Introduction to the session: Rethinking Models of MS: Bridging the Gaps Between Pathology, Prediction, and Progress Tanja Kuhlmann |
||
| 15:45-16:05 | Modeling MS pathology: Going beyond EAE Hans Lassmann |
||
| 16:05-16:25 | Modeling the future of MS research: clinical clues that help or mislead Andrew Chan |
||
| 16:25-16:45 | Modeling the future of MS research: MRI clues that help or mislead Nicola De Stefano |
||
| 16:45-17:15 | Q & A, Discussion | ||
| 17:15-17:30 | Break |
||
| 17:30-19:15 | SESSION-4: Impact of hormones in neuroimmunology Discussants & Chairs: Sandra Vukusic, Ayşe Altıntaş, Gülşen Akman Demir |
||
| 17:30-17:45 | Introduction to the session: Sex Matters in MS: Potential therapeutic inertia affecting treatment in women with MS compared to men Sandra Vukusic |
||
| 17:45-18:05 | What might have been missed by not running sex-specific clinical trials in MS? Kerstin Hellwig |
||
| 18:05-18:25 | Impact of sex hormone switches in neuroimmunology – MS and beyond Burcu Zeydan |
||
| 18:25-18:45 | Impact of sex hormones on animal models of MS Manu Rangachari |
||
| 18:45-19:15 | Q & A, Discussion | ||
| 19:30 | Opening Reception | ||
| 08:00-09:00 | Oral Abstract Presentations | ||
| 09:05-11:00 | SESSION - 5: Myelin gets sick early in MS Discussants & Chairs: Catherine Lubetzki, Aslı Tuncer, Murat Kürtüncü |
||
| 09:05-09:20 | Introduction to the session- Myelin is not the only actor in MS Catherine Lubetzki |
||
| 09:20-09:40 | More questions than answers in remyelination trials in MS Peter Calabresi |
||
| 09:40-10:00 | Interactions between astrocytes and oligodendroglia in MS Daniel Reich |
||
| 10:00-10:20 | PET as a single quantitative remyelination marker for clinical trials Bruno Stankoff |
||
| 10:20-10:50 | Q & A, Discussion | ||
| 10:50-11:05 | Break |
||
| 11:05-12:50 | SESSION - 6: Simplifying the clinical phenotype definitions of MS Discussants & Chairs: Andrew J. Solomon, Rana Karabudak, Refik Pul |
||
| 11:05-11:20 | Introduction to the session: Has the new diagnostic criteria increased or decreased the risk of misdiagnosis in MS globally? Andrew J. Solomon |
||
| 11:20-11:40 | Single agnostic definition of MS – the imaging-clinical continuum Orhun Kantarci |
||
| 11:40-12:00 | Extremes of MS - Aggressive versus benign Ellen Mowry |
||
| 12:00-12:20 | Separation of targets for differing trial endpoints – PIRA vs. RAW Daniel Ontaneda |
||
| 12:20-12:50 | Q & A, Discussion | ||
| 12:50-13:50 | Lunch & In-Lunch Satellite Symposium | ||
| 13:50-15:30 | SESSION-7: Defining MS phenotypes by biomarkers Discussants & Chairs: Eric Thouvenot, Jorge Correale, Ugur Uygunoglu |
||
| 13:50-14:05 | Introduction to the session: From Missteps to Milestones: Rethinking Biomarkers in MS Phenotyping Eric Thouvenot |
||
| 14:05-14:25 | Biomarkers of pre-symptomatic disease in MS – lessons from RIS Christine Lebrun-Frenay |
||
| 14:25-14:45 | Pre- and post-symptomatic immunophenotypes of MS Heinz Wiendl |
||
| 14:45-15:05 | Should AI care for our definitions of MS phenotypes? Vilas Menon |
||
| 15:05-15:35 | Q & A, Discussion | ||
| 15:35-15:50 | Break |
||
| 15:50-17:35 | SESSION-8: Risk factor mitigation in MS Discussants & Chairs: Nikolaos Grigoriadis, Eda Tahir Turanlı, Yeşim Beckman |
||
| 15:50-16:05 | Introduction to the session: Mitigation Starts with Recognition: The Cost Of not addressing risk of MS Nikolaos Grigoriadis |
||
| 16:05-16:25 | Lessons from our mistakes in epidemiology of MS Alberto Ascherio |
||
| 16:25-16:45 | Is the gut the new solution for the brain? David Hafler |
||
| 16:45-17:05 | EBV vaccination or microbiome transfer – which is the better path forward for MS prevention? Thomas Berger |
||
| 17:05-17:35 | Q & A, Discussion | ||
| 17:35-17:50 | Break |
||
| 17:50-19:35 | SESSION - 9: Larger than life clinical trials in MS Discussants & Chairs: Ludwig Kappos, Hans-Peter Hartung, Melih Tutuncu |
||
| 17:50-18:05 | Introduction to the session: Decades of Experience in MS Therapeutic Trials: Key Lessons Learned Ludwig Kappos |
||
| 18:05-18:25 | Give me the ideal clinical trial in MS - what is amiss in the past ones? Xavier Montalban |
||
| 18:25-18:45 | Real value of harmonization of imaging for clinical trials Maria Pia Sormani |
||
| 18:45-19:05 | Loosing specificity while looking for commonality and sensitivity in MS trials Jiwon Oh |
||
| 19:05-19:35 | Q & A, Discussion | ||
| 20:00 | Leave for dinner | ||
| 08:00-08:45 | Morning Satellite Symposium – Alexion Chair: Ayşe Altıntaş |
||
| Targeting the Source: Complement Blockade in NMOSD Jin Nakahara, Melih Tütüncü |
|||
| 08:45-10:15 | SESSION - 10: Don’t ignore cognition in MS Discussants & Chairs: Anat Achiron, Najib Kissani, Serkan Demir |
||
| 08:45-08:55 | Introduction to the session: We protected the brain but lost the mind in MS! Anat Achiron |
||
| 08:55-09:15 | Complex imaging signatures of cognitive decline in MS Korhan Buyukturkoglu |
||
| 09:15-09:35 | Impact of ethnicity on cognition in MS Nabeela Nathoo |
||
| 09:35-09:55 | Roadblocks to treating cognition sufficiently in MS Claire Riley |
||
| 09:55-10:15 | Q & A, Discussion | ||
| 10:15-10:30 | Break |
||
| 10:30-12:00 | SESSION - 11: Imaging developments in MS Discussants & Chairs: Nur Yüceyar, Mohammad Ali Sahraian, Serhat Okar |
||
| 10:30-10:40 | Introduction to the session: Rethinking what we are measuring by imaging by MRI and PET in MS Serhat Okar |
||
| 10:40-11:00 | From 2D to 3D understanding of MS lesion specificty Darin Okuda |
||
| 11:00-11:20 | What is going on in the deep gray matter in MS Christina Azevedo |
||
| 11:20-11:40 | What is going on in the normal appearing white matter in MS Cristina Granziera |
||
| 11:40-12:00 | Q & A, Discussion | ||
| 12:00-13:00 | Lunch & In-Lunch Satellite Symposium | ||
| 13:00-14:45 | SESSION-12: Propensity for autoimmunity Discussants & Chairs: Hayrettin Tumani, Dicle Güç, TBA |
||
| 13:00-13:15 | Introduction to the session: Common Risk Pathways in Autoimmunity Hayrettin Tumani |
||
| 13:15-13:35 | A bioinformatics architecture of susceptibility to autoimmunity Mika Gustaffson |
||
| 13:35-13:55 | Role of TCR as key to autoimmunity Batu Erman |
||
| 13:55-14:15 | Autoimmune mechanisms of neurodegeneration
Katerina Akassoglou |
||
| 14:15-14:45 | Q & A, Discussion | ||
| 14:45-15:00 | Break |
||
| 15:00-16:45 | SESSION-13: Don’t ignore the children Discussants & Chairs: Jacqueline Palace, Anne-Katrin Proebstel, Sema Saltık |
||
| 15:00-15:15 | Introduction to the session: From Childhood to Adulthood: Unraveling CNS Autoimmunity Across Ages Jacqueline Palace |
||
| 15:15-15:35 | Why are CNS inflammatory disorders more aggressive in children Naila Makhani |
||
| 15:35-15:55 | Autoimmune leukoencephalopathies in children Silvia Tenembaum |
||
| 15:55-16:15 | Differences in children’s brain imaging compared to adults in MS Matilde Inglese |
||
| 16:15-16:45 | Q & A, Discussion | ||
| 16:45-17:00 | Break |
||
| 17:00-19:00 | SESSION - 14: Advances in MOG and NMO autoimmunity Discussants & Chairs: Kazuo Fujihara, Nasrin Asgari, Paulus Rommer |
||
| 17:00-17:15 | Introduction to the session: Lessons From the Era of NMOSD as Distinct From MS at the Turn of the Millennium Kazuo Fujihara |
||
| 17:15-17:35 | The Many Faces of MOG autoimmunity Romain Marignier |
||
| 17:35-17:55 | Mechanism of action of MOG antibodies Orhan Aktaş |
||
| 17:55-18:15 | What does MOG autoimmunity teach us about post-inflammatory CNS diseases? Axel Petzold |
||
| 18:15-18:35 | The strange case of MOG- Why does it not progress like MS? Eoin Flanagan |
||
| 18:35-19:00 | Q & A, Discussion | ||
| 19:00-20:00 | SESSION-15: Summary of the meeting Chairs: Serhan Sevim, Nilüfer Kale İçen Speakers: Serkan Özben, Meral Seferoğlu, Mesude Tütüncü, Gülgün Uncu, Ahmet Kasım Kılıç |
||
| 20:15 | Departure for Farewell Dinner | ||